RG7112, a Small-Molecule Inhibitor of MDM2, Enhances Trabectedin Response in Soft Tissue Sarcomas

The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.

Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity

Steel, G. G., & Peckham, M. (1979) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(79)90044-0 · Cited by 913 · see citing works

Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Hogendoorn, P. C. W., Athanasou, N. A., Bielack, S., de Álava, E., Tos, A. P. D., Ferrari, S., Gelderblom, H. A. J., Grimer, R. J., Hall, K. S., Hassan, A. B., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq223 · Cited by 716 · see citing works

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708 · see citing works

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571 · see citing works

Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer

Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, E., Lisyanskaya, A. S., Makhson, A. N., Rolski, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4037 · Cited by 395 · see citing works

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair

Takebayashi, Y., Pourquier, P., Zimonjic, D. B., Nakayama, K., Emmert, S., Ueda, T., Urasaki, Y., Kanzaki, A., Akiyama, S., Popescu, N. C., et al. (2001) · Nature Medicine · doi:10.1038/91008 · Cited by 348 · see citing works

MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models

Tovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2807 · Cited by 283 · see citing works

Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells

Germano, G., Frapolli, R., Simone, M., Tavecchio, M., Erba, E., Pesce, S., Pasqualini, F., Grosso, F., Sanfilippo, R. G., Casali, P. G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2335 · Cited by 266 · see citing works

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action

Erba, E., Bergamaschi, D., Bassano, L., Damia, G., Ronzoni, S., Faircloth, G. T., & D'Incalci, M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00357-9 · Cited by 262 · see citing works

Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group

Cesne, A. L., Judson, I. R., Crowther, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.14.2676 · Cited by 259 · see citing works

Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Casali, P. G., & Blay, J. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq209 · Cited by 256 · see citing works

Gene Expression Profiling of Liposarcoma Identifies Distinct Biological Types/Subtypes and Potential Therapeutic Targets in Well-Differentiated and Dedifferentiated Liposarcoma

Singer, S., Socci, N. D., Ambrosini, G., Sambol, E. B., DeCarolis, P. L., Wu, Y. V., O’Connor, R., Maki, R. G., Viale, A. J., Sander, C., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0584 · Cited by 249 · see citing works

Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies

Linch, M. D., Miah, A. B., Thway, K., Judson, I. R., & Benson, C. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.26 · Cited by 216 · see citing works

Cross-Talk between Nucleotide Excision and Homologous Recombination DNA Repair Pathways in the Mechanism of Action of Antitumor Trabectedin

Herrero, A. B., Martı́n-Castellanos, C., Marco, E., Gago, F., & Moreno, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0179 · Cited by 172 · see citing works

Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A

Müller, C. R., Paulsen, E. B., Noordhuis, P., Pedeutour, F., Sæter, G., & Myklebost, O. (2007) · International Journal of Cancer · doi:10.1002/ijc.22643 · Cited by 119 · see citing works

Predicting breast cancer recurrence

Stenkvist, B., Bengtsson, E. W., Dahlqvist, B., EKLUND, G. A., Eriksson, O., Jarkrans, T., & Nordin, B. G. (1982) · Cancer · doi:10.1002/1097-0142(19821215)50:12 · Cited by 90 · see citing works

Ecteinascidin-743 inhibits activated but not constitutive transcription.

Friedman, D., Hu, Z., Kolb, E. A., Gorfajn, B., & Scotto, K. W. (2002) · PubMed · Cited by 89 · see citing works

DNA and Non-DNA Targets in the Mechanism of Action of the Antitumor Drug Trabectedin

David‐Cordonnier, M., Gajate, C., Olmea, O., Laine, W., de la Iglesia-Vicente, J., Perez, C., Cuevas, C., Otero, G., Manzanares, I., Bailly, C., et al. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.08.009 · Cited by 80 · see citing works

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines

Ohnstad, H. O., Paulsen, E. B., Noordhuis, P., Berg, M., Lothe, R. A., Vassilev, L. T., & Myklebost, O. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-211 · Cited by 78 · see citing works

Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression.

Takebayashi, Y., Goldwasser, F., Urasaki, Y., Kohlhagen, G., & Pommier, Y. (2001) · PubMed · Cited by 62 · see citing works

Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma

Procopio, A. D., Strizzi, L., Vianale, G., Betta, P., Puntoni, R., Fontana, V., Tassi, G., Gareri, F., & Mutti, L. (2000) · Genes Chromosomes and Cancer · doi:10.1002/1098-2264(2000)9999:9999 · Cited by 52 · see citing works

Absence or low number of telomere repeats at junctions of dicentric chromosomes

Wan, T. S. K., Martens, U. M., Poon, S. S. S., Tsao, S., Ha, S., & Lansdorp, P. M. (1999) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199901)24:1 · Cited by 45 · see citing works

Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma

Ohnstad, H. O., Castro, R., Sun, J., Heintz, K., Vassilev, L. T., Bjerkehagen, B., Kresse, S. H., Meza‐Zepeda, L. A., & Myklebost, O. (2012) · Cancer · doi:10.1002/cncr.27837 · Cited by 42 · see citing works

Extreme sensitivity to Yondelis® (Trabectedin, ET‐743) in low passaged sarcoma cell lines correlates with mutated p53

Moneo, V., Serelde, B. G., Fominaya, J. M., Martínez-Leal, J. F., Blanco‐Aparicio, C., Romero, L., Sánchez‐Beato, M., Cigudosa, J. C., Tercero, J. C., Piris, M. A., et al. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21073 · Cited by 40 · see citing works

Nilotinib Counteracts P-Glycoprotein-Mediated Multidrug Resistance and Synergizes the Antitumoral Effect of Doxorubicin in Soft Tissue Sarcomas

Villar, V. H., Vögler, O., Martínez-Serra, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037735 · Cited by 40 · see citing works

Characterization of Liposarcoma Cell Lines for Preclinical and Biological Studies

Stratford, E. W., Castro, R., Daffinrud, J., Skårn, M., Lauvrak, S. U., Munthe, E., & Myklebost, O. (2012) · Sarcoma · doi:10.1155/2012/148614 · Cited by 40 · see citing works

The Activity of Trabectedin As a Single Agent or in Combination with Everolimus for Clear Cell Carcinoma of the Ovary

Mabuchi, S., Hisamatsu, T., Kawase, C., Hayashi, M., Sawada, K., Mimura, K., Takahashi, K., Takahashi, T., Kurachi, H., & Kimura, T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2987 · Cited by 37 · see citing works

New drugs and combinations for the treatment of soft-tissue sarcoma: a review

von Mehren, M., & Somaiah (2012) · Cancer Management and Research · doi:10.2147/cmar.s23257 · Cited by 26 · see citing works

Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: New molecular insight into the mechanism of action

Martínez-Serra, J., Maffiotte, E., Martín‐Broto, J., Bex, T., Navarro-Palou, M., Ros, T., Plazas, J. M., Vögler, O., Gutierrez, A. M., Amat, J. C., et al. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.02.035 · Cited by 20 · see citing works

A Systems Biology Approach to Characterize the Regulatory Networks Leading to Trabectedin Resistance in an In Vitro Model of Myxoid Liposarcoma

Uboldi, S., Calura, E., Beltrame, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035423 · Cited by 19 · see citing works

Analysis of DNA Repair–Related Genes in Breast Cancer Reveals CUL4A Ubiquitin Ligase as a Novel Biomarker of Trabectedin Response

García, M. J., Saucedo-Cuevas, L. P., Muñoz‐Repeto, I., Fernández, V., Robles, M. J., Domingo, S., Palacios, J., Aracil, M., Nieto, A., Tercero, J. C., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0768 · Cited by 18 · see citing works

Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives

Fang, Y., Liao, G., & Yu, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.003 · Cited by 106 · see citing works

Helping the released guardian: Drug combinations for supporting the anticancer activity of HDM2 (MDM2) antagonists

Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L. (2019) · Cancers · doi:10.3390/cancers11071014 · Cited by 46 · see citing works

CDK4 inhibition diminishes p53 activation by MDM2 antagonists

Sriraman, A., Dickmanns, A., Najafova, Z., Johnsen, S. A., & Dobbelstein, M. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0968-0 · Cited by 40 · see citing works

Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors

Frapolli, R., Tamborini, E., Virdis, E., Bello, E., Tarantino, E., Marchini, S., Grosso, F., Sanfilippo, R. G., Gronchi, A., Tercero, J. C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0317 · Cited by 28 · see citing works

Supplementary Fig. S3 from Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

Forni, C., Minuzzo, M., Virdis, E., et al. (2023) · doi:10.1158/1535-7163.22485858

Supplementary Fig. S1 from Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

Forni, C., Minuzzo, M., Virdis, E., et al. (2023) · doi:10.1158/1535-7163.22485864.v1

Supplementary Fig. S2 from Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

Forni, C., Minuzzo, M., Virdis, E., et al. (2023) · doi:10.1158/1535-7163.22485861

Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin

Bello, E., Brich, S., Craparotta, I., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0550-2 · Cited by 14 · see citing works